Combination therapy for early-stage rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of treatments for rectal cancer that has not spread beyond the rectum. The goal is to shrink or eliminate the cancer before surgery, potentially avoiding the need for a permanent colostomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have rectal cancer that is adenocarcinoma and located within 5 cm of the anal opening.
- Your cancer must be stage T1-3N0M0, meaning it has not spread to lymph nodes or distant organs.
- You must not have received any previous treatment for this cancer, including radiation, chemotherapy, or surgery.
- You must be in good general health, with adequate organ function (bone marrow, liver, kidneys).
- You must agree to use effective contraception during the study and for 12 months after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (tislelizumab) and standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to help shrink or eliminate the tumor so surgery might be less invasive or not needed, allowing you to keep your rectum.
This trial tests a new combination of short-course radiation, an immunotherapy drug called ivonescimab, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a combination of short-course radiation, internal radiation (brachytherapy), and several drugs to shrink rectal cancer before surgery. The goal is to improve outcomes and potentially avoid more extensive surgery.
This trial tests a new approach for advanced low rectal cancer. You'll receive a combination of chemotherapy, immunotherapy, and radiation before surgery, which may help shrink the tumor and make surgery easier.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (serplulimab) for people with rectal cancer that has spread to just a few spots in the body (no more than 5 tumors in up to 2 locations). It aims to see if this approach is safe and effective.
This trial tests a combination of short-course radiation, chemotherapy, and two types of immunotherapy (HLX07 and Serplulimab) before surgery for advanced rectal cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
Hear when a new Rectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.